Beta Bionics insider plans sale of 5,327 shares

A Beta Bionics insider filed a Rule 144 notice to sell shares mainly to cover tax obligations from recently vested stock units.

Rhea-AI Filing Summary

Beta Bionics, Inc. (BBNX) insider Mark Hopman has filed a Rule 144 notice for a proposed sale of 5,327 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an estimated aggregate value of $103,423.71 as of September 2, 2026.

The shares relate to restricted stock units vesting under a registered plan as compensation for services to Beta Bionics, and the filing describes the transaction as a sell-to-cover for taxes owed on recent vesting of stock unit awards. The notice also lists prior sales in the past three months totaling several thousand shares.

Key Figures

Shares proposed to be sold: 5,327 shares Proposed sale value: $103,423.71 Prior sale on June 2, 2026: 5,329 shares for $67,183.24 +3 more

6 metrics

Shares proposed to be sold 5,327 shares Planned Rule 144 sale of Beta Bionics common stock

Proposed sale value $103,423.71 Aggregate market value for 5,327 shares as of September 2, 2026

Prior sale on June 2, 2026 5,329 shares for $67,183.24 Common stock sold by Mark Hopman in the past 3 months

Prior sale on June 4, 2026 275 shares for $3,385.25 Common stock sold by Mark Hopman in the past 3 months

Prior sale on June 24, 2026 1,258 shares for $18,880.44 Common stock sold by Mark Hopman in the past 3 months

Date of Notice September 3, 2026 Date the Rule 144 notice was signed and filed

Key Terms

Rule 144, Restricted Stock Units, sell-to-cover

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Units financial

"Restricted Stock Units vesting under registered plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

sell-to-cover financial

"This is a sell-to-cover transaction for taxes owed"

Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Beta Bionics (BBNX)?

The filing discloses that Mark Hopman plans to sell 5,327 shares of Beta Bionics common stock under Rule 144, tied to vested restricted stock units, mainly as a sell-to-cover transaction for taxes owed on recent vesting.

How many BBNX shares are proposed to be sold and at what value?

The notice covers a proposed sale of 5,327 shares of Beta Bionics common stock with an indicated aggregate value of $103,423.71 as of September 2, 2026, to be sold on NASDAQ through Morgan Stanley Smith Barney LLC.

What is the reason given for the planned Beta Bionics share sale?

The remarks state that the transaction is a sell-to-cover for taxes owed related to the recent vesting of stock unit awards granted by Beta Bionics, indicating the shares stem from restricted stock units vesting under a registered plan.

What prior Beta Bionics (BBNX) sales by Mark Hopman are reported in the last 3 months?

The filing lists three prior common stock sales: 5,329 shares on June 2, 2026 for $67,183.24, 275 shares on June 4, 2026 for $3,385.25, and 1,258 shares on June 24, 2026 for $18,880.44.

Who is the broker and market for the planned BBNX share sale?

The proposed sale of 5,327 Beta Bionics common shares is to be executed through Morgan Stanley Smith Barney LLC at 1 New York Plaza, New York, with the shares listed for trading on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 05:27 PM Accepted by SEC EDGAR 09/03/2026 - 05:23 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002048497
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	BETA BIONICS, INC.
SEC File Number	001-42491
Address of Issuer	11 HUGHES IRVINE CALIFORNIA 92618
Phone	949-427-7785
Name of Person for Whose Account the Securities are To Be Sold	Mark Hopman
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza New York NY 10004	5327	103423.71	45123368	09/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/01/2026	Restricted Stock Units vesting under registered plan	Issuer			5327	09/01/2026	Compensation for services rendered to Issuer

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Mark Hopman c/o Beta Bionics, Inc. 11 Hughes Irvine CA 92618	Common Stock	06/02/2026	5329	67183.24
Mark Hopman c/o Beta Bionics, Inc. 11 Hughes Irvine CA 92618	Common Stock	06/04/2026	275	3385.25
Mark Hopman c/o Beta Bionics, Inc. 11 Hughes Irvine CA 92618	Common Stock	06/24/2026	1258	18880.44

144: Remarks and Signature

Remarks	This is a sell-to-cover transaction for taxes owed related to recent vesting of stock unit awards granted by the Issuer.
Date of Notice	09/03/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Stephen Feider, Attorney-in-Fact
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)